CORONA REMEDIES LIMITED Share Price

₹ 2,155.20

+₹5.60 (0.26%)
1D
Last updated 02 Nov, 2026, 15:29 IST
NSE: CORONA
|
Pharmaceuticals

CORONA REMEDIES LIMITED Share Price Today

As of 2 Nov 2026, CORONA REMEDIES LIMITED share price is ₹2,155.20. The stock opened at ₹2,149.90, compared to its previous close of ₹2,149.60. During today's trading session, CORONA REMEDIES LIMITED share price moved in the range of ₹2,104.20 to ₹2,205.00, with an average price of ₹2,154.60 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,336.60 and a high of ₹2,292.40. On the performance front, CORONA REMEDIES LIMITED share price has increased by 24.50% over the last six months and is up 49.44% on a year-on-year basis.

Share price over the last 1 day fell from 2155.70 to 2155.20, ranging between 2126.00 and 2203.60.
₹2,104.20
0.26% up today
₹2,205.00
1D LOW
1D HIGH

CORONA REMEDIES LIMITED Stock Insights

Latest Earning
Op Profit TrendUp by 0.49% QoQ
Latest Earning
Net Profit TrendUp by 0.33% QoQ
Latest Earning
Revenue TrendUp by 4.25% QoQ
Stock Performance
OutperformingBeat Nifty by 0.77 % in last 1 month
Shareholding Pattern
DIIDII decreased stake by 2.39%
Shareholding Pattern
FIIFII increased stake by 16.00%
CORONA REMEDIES LIMITED stock performance
Open₹2,149.90
High₹2,205.00
Low₹2,104.20
Prev. close₹2,149.60
CORONA REMEDIES LIMITED trading activity
Volume37,865
Average traded price₹2,170.76
Last traded time03:29:45 02 Nov
Last traded quantity1
Circuit
L
H
₹1,719.70
₹2,579.50
52-week
L
H
₹1,336.60
₹2,292.40
Mkt Cap Cr
13,125.26
P/E
65.95
P/B
17.57
ROA
16.6%
ROE
25.71%
ROCE
30.38%
Quick Ratio
0.62
EV/EBITDA
40.5

Based on fundamentals, this stock's

Performance: 5 out of 5, Excellent
Performance
Excellent
Corona Remedies outperforming all market indices
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Corona Remedies appears overvalued compared to its peers
Earnings: 5 out of 5, Excellent
Earnings
Excellent
Corona Remedies revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,26,661.7438.834.789.61%13.79%18.65%2.3122.27
Divis Laboratories2,57,902.7388.1715.3914.6%15.32%19.56%3.558.97
Torrent Pharmaceuticals1,76,306.2184.09.64.7%11.42%11.37%0.7533.6
Laurus Labs1,29,242.6897.021.3311.58%22.11%20.91%0.6854.77
Zydus Lifesciences1,24,089.4827.024.588.57%18.59%17.35%0.9116.42
Dr. Reddy's Laboratories1,12,698.5340.842.94.79%7.21%8.58%1.3519.05
Cipla1,11,486.1439.063.156.6%8.18%10.8%2.521.03
Mankind Pharma1,02,796.6045.425.857.82%12.76%14.68%0.7425.01
Aurobindo Pharma96,536.9026.022.556.34%9.25%11.76%1.1512.38
Lupin91,870.1616.554.0914.47%23.76%24.88%1.429.83

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

CORONA REMEDIES LIMITED Company Background

ISIN
INE02ZQ01018
Sector Market Cap
₹ 13,125.26 Cr

Corona Remedies Limited is an India-based pharmaceutical formulation company. The Company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory). Its diverse product portfolio comprises approximately 67 brands catering to a range of therapeutic areas. It has four dosage forms in pain management formulations, which it offers in the form of tablets, capsules, sprays and injections for treatments associated with musculoskeletal spasms and diabetes. It holds brands across the women’s healthcare lifecycle, from adolescence to infertility, pregnancy, post-pregnancy and pre- and post-menopause categories. Its brands include such as C-HOP; Trazer; COR; Cortel; Rosuless; Bisobis; Sitabite; Dapabite; Fur; Voglibite; Angiwell; Stimucor; Argihope, and others.

CORONA REMEDIES LIMITED Financial Highlights

  • Revenue: CORONA REMEDIES LIMITED reported revenue of ₹1,413.83 crore in FY26 vs ₹1,202.35 crore in FY25. It showed an increase of 17.59% on a yearly basis.
  • Operating Profit: CORONA REMEDIES LIMITED reported an operating profit of ₹240.42 crore in FY26 vs ₹198.53 crore in FY25. It showed an increase of 21.10% on a year-on-year basis.
  • Net Profit: CORONA REMEDIES LIMITED reported a net profit of ₹185.12 crore in FY26 vs ₹149.43 crore in FY25. It showed an increase of 23.88% on a yearly basis.

CORONA REMEDIES LIMITED Quarterly Result Highlights

  • CORONA REMEDIES LIMITED reported revenue of ₹443.65 crore in Sep 2026, compared with ₹425.58 crore in Jun 2026, representing an increase of 4.25% on a quarter-on-quarter (QoQ) basis.
  • CORONA REMEDIES LIMITED reported an operating profit of ₹80.75 crore in Sep 2026, compared with ₹80.36 crore in Jun 2026, representing an increase of 0.49% on a quarter-on-quarter (QoQ) basis.
  • CORONA REMEDIES LIMITED reported a profit of ₹60.31 crore in Sep 2026, compared with ₹60.11 crore in Jun 2026, reflecting an increase of 0.33% on a QoQ basis.
  • The earnings per share (EPS) of CORONA REMEDIES LIMITED stood at ₹30.27 during Sep 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
69.00%
FII
4.21%
Other DII
0.39%
Retail and other
10.34%
Mutual funds
16.06%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 20251.84%
Mar 20262.25%
Jun 20263.63%
Sep 20264.21%

CORONA REMEDIES LIMITED Investment Returns

1 day
-3.06%
1 week
+4.80%
1 month
+2.68%
1 year
+49.44%
3 years
+49.44%
5 years
+49.44%

CORONA REMEDIES LIMITED Share Price History

CORONA REMEDIES LIMITED share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
30 Oct 26
₹2,217.40 / ₹2,149.60
-3.06%
29 Oct 26
₹2,182.00 / ₹2,217.40
+0.76%
28 Oct 26
₹2,200.00 / ₹2,200.60
+2.26%
27 Oct 26
₹2,041.00 / ₹2,152.00
+5.42%
Show more

CORONA REMEDIES LIMITED Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,403.18₹1,196.42₹1,014.47₹884.05
Other Income₹10.65₹5.93₹6.46₹7.05
Total Revenue₹1,413.83₹1,202.35₹1,020.93₹891.10
Total Expenses₹1,154.58₹1,004.20₹902.46₹780.44
Profit Before Tax₹240.42₹198.53₹118.48₹110.89
Tax₹55.30₹49.10₹27.98₹25.96
Profit After Tax₹185.12₹149.43₹90.50₹84.93
EPS - Basic₹30.27₹24.43₹14.80₹14.57
EPS - Diluted₹30.27₹24.43₹14.80₹14.57

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹240.42₹198.53₹118.48₹110.89
Income before WC changes₹284.77₹250.84₹165.35₹133.44
Change in Assets-₹32.73-₹51.80-₹11.87-₹33.63
Change in Liabilities₹26.86₹34.73₹21.19₹28.72
Change in WC-₹5.87-₹17.07₹9.32-₹4.92
Cash flow from Operations₹229.48₹190.49₹156.76₹102.70
Cash flow from Investing-₹256.15-₹83.86-₹266.64-₹50.25
Cash flow from Financing₹25.28-₹106.57₹98.55-₹44.75
Total Cash Flow-₹1.39₹0.06-₹11.34₹7.71
Cash (Start of the year)₹3.22₹3.16₹14.49₹6.82
Cash (End of the year)₹1.83₹3.22₹3.16₹14.49

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹856.83₹590.99₹540.66₹303.54
Current Assets₹348.31₹338.87₹289.92₹291.49
Total Assets₹1,205.14₹929.86₹830.58₹595.02
Current Liabilities₹361.17₹239.59₹224.19₹137.37
Net Current Asset-₹12.86₹99.28₹65.72₹154.12
Non-Current Liabilities₹97.11₹83.93₹125.98₹49.13
Equity Capital₹746.86₹606.34₹480.41₹408.52
Total Equity & Liabilities₹1,205.14₹929.86₹830.58₹595.02

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,403.18₹1,196.42₹1,014.47₹884.05
Other Income₹10.65₹5.93₹6.46₹7.05
Total Revenue₹1,413.83₹1,202.35₹1,020.93₹891.10
Total Expenses₹1,154.58₹1,004.20₹902.46₹780.44
Profit Before Tax₹240.15₹198.15₹118.48₹110.66
Tax₹55.30₹49.10₹27.98₹25.96
Profit After Tax₹184.85₹149.05₹90.50₹84.70
EPS - Basic₹30.22₹24.37₹14.80₹14.53
EPS - Diluted₹30.22₹24.37₹14.80₹14.53

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹240.15₹198.15₹118.48₹110.66
Income before WC changes₹284.77₹250.84₹165.35₹133.44
Change in Assets-₹32.73-₹51.80-₹11.87-₹33.63
Change in Liabilities₹26.86₹34.73₹21.19₹28.72
Change in WC-₹5.87-₹17.07₹9.32-₹4.91
Cash flow from Operations₹229.48₹190.49₹156.76₹102.70
Cash flow from Investing-₹256.15-₹83.86-₹266.65-₹50.25
Cash flow from Financing₹25.28-₹106.57₹98.54-₹44.75
Total Cash Flow-₹1.39₹0.06-₹11.34₹7.71
Cash (Start of the year)₹3.22₹3.16₹14.49₹6.82
Cash (End of the year)₹1.83₹3.22₹3.16₹14.49

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹855.94₹590.37₹540.42₹303.31
Current Assets₹348.31₹338.87₹289.92₹291.49
Total Assets₹1,204.25₹929.24₹830.34₹594.80
Current Liabilities₹361.17₹239.59₹224.19₹137.37
Net Current Asset-₹12.86₹99.28₹65.73₹154.12
Non-Current Liabilities₹97.11₹83.93₹125.98₹49.13
Equity Capital₹745.97₹605.72₹480.18₹408.29
Total Equity & Liabilities₹1,204.25₹929.24₹830.34₹594.80
* All values are in INR Crore
CORONA REMEDIES LIMITED market depth
Bid quantityBid priceAsk priceAsk quantity
002171.13
0000
0000
0000
0000
Total bid quantity0
Total ask quantity3
CORONA REMEDIES LIMITED technical summary
Bearish indicators1
Neutral indicators6
Bullish indicators1
OverallNeutral
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict
RSI (14)
57.18
Neutral
ATR (14)
68.3
Neutral
STOCH(9,6)
62.01
Neutral
STOCH RSI (14)
62.01
Neutral
ADX(9)
34.9
Bearish
UO(9)
60.58
Neutral
ROC(12)
6.09
Bullish
WillR(14)
-32.52
Neutral
Period
Simple value
Exponential vaue
5D
2152.2
2150.41
10D
2089.07
2115.78
20D
2059.86
2093.53
50D
2100.96
2080.14
100D
2048.71
2035.46
Volume trend — traded volume by day
2 Nov0L
30 Oct0L
29 Oct0L
28 Oct0L
27 Oct0L
26 Oct0L
Average0L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

CORONA REMEDIES LIMITED
Pharmaceuticals
Add Stock
Add Another

CORONA REMEDIES LIMITED Latest News

3 months ago
Corona Remedies share price rises ahead of Q2 results announcement
Showing news item 1 of 1

CORONA REMEDIES LIMITED Share Price FAQs

Please be aware that CORONA REMEDIES LIMITED stock prices are subject to continuous fluctuations due to various factors.